Addition Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Addition Therapeutics brings 3 presentations to ESGCT 2026 in Hamburg. Its work centres on inserting whole genes with an RNA-mediated retrotransposase carried by lipid nanoparticles, giving durable protein production from the liver in mice and non-human primates. Programmes shown include engineered incretin agonists and a GLA transgene for Fabry disease.
| Organization | ESGCT 2026 Attendance |
|---|---|
Develops PRINT, an all-RNA platform delivered by lipid nanoparticles that uses an R2 retrotransposase to insert therapeutic genes durably. | Talk Thu Oct 29 10:00am–10:30am Precise, RNA-mediated insertion of transgenes using an R2 retrotransposase yields stable, durable, and therapeutic hepatic protein expression, from mice to NHPs Gene and epigenome editingVectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Durable In Vivo Expression of Engineered Incretin Agonists Using PRINT Poster Thu Oct 29 2:00pm–4:00pm Preclinical proof-of-concept of treatment for Fabry disease via precise RNA-mediated insertion of a GLA transgene Rare and inherited diseaseGene and epigenome editing |
Instantly find 20 buyers from Addition Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction